Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Schmidt, F. P.; Glaser, N. J.; Schreiner, O. et al.
"Do not rescuscitate"- Consequences of the Introduction of a standardized Form of Therapy Limitations in the clinical PracticeDEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. Bd. 140. H. 15. 2015 S. E159-E165
Koch, Felix P.; Goetze, Elisabeth; Kumar, Vinay V. et al.
A bar-retained overdenture as an external fixator device in a three-dimensional CAD/CAM-based surgical reconstruction of the mandibleJOURNAL OF CRANIO-MAXILLOFACIAL SURGERY. Bd. 43. H. 8. 2015 S. 1447-1451
Kaemmerer, P. W.; Rahimi-Nedjat, R. K.; Ziebart, T. et al.
A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions-clinical evaluation and review of the literatureCLINICAL ORAL INVESTIGATIONS. Bd. 19. H. 2. 2015 S. 459-466
Weiler, Sofia; Wolf, Thomas; Pinna, Federico et al.
A gene signature defines chromosomal instability (CIN) and poor survival in liver cancer patientsCANCER RESEARCH. Bd. 75. 2015
Ramalingam, S.; Goss, G.; Rosell, R. et al.
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)ANNALS OF ONCOLOGY. Bd. 26. H. 8. 2015 S. 1741-1748
Korfei, Martina; Skwarna, Sylwia; Henneke, Ingrid et al.
Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosisTHORAX. Bd. 70. H. 11. 2015 S. 1022-1032
Hayashi, Tetsutaro; Seiler, Roland; Bell, Robert H. et al.
ACTIVATION OF IFN/STAT1 SIGNALING IN CISPLATIN/GEMCITABINE RESISTANT BLADDER CANCERJOURNAL OF UROLOGY. Bd. 193. H. 4. 2015 S. E606-E606
Epp, K.; Schaefer, L.; Theobald, M. et al.
Acute GvHD after Alemtuzumab based conditioning regimen correlates with persistence of GPI-anchor negative, functionally altered regulatory T cellsBONE MARROW TRANSPLANTATION. Bd. 50. 2015 S. S51-S51
Andre, Thierry; de Gramont, Armand; Vernerey, Dewi et al.
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC StudyJOURNAL OF CLINICAL ONCOLOGY. Bd. 33. H. 35. 2015 S. 4176-+
Battista, Marco Johannes; Schmidt, Marcus; Rieks, Nicole et al.
Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. Bd. 141. H. 3. 2015 S. 555-562